Our findings need to be confirmed prospectively, particularly in breast cancer patients stratified for stage and therapy, but provide support for the use of a BRCA locus-specific LOH assay to predict primary response to platinums, and potentially PARP inhibitors, in patients with germline BRCA1 and BRCA2 mutations. The gene discussed is BRCA2; the disease is breast carcinoma.